US › Healthcare

PepGen Ltd (PEPG)

US · Healthcare · Biotechnology

$2.97+2.41%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-17.8M

EPS

$-0.26

EPS estimate

$-0.30

EPS came in at -0.26 against a street estimate of -0.30 — a beat of 13.3%.

Key statistics

Market cap

$200.9M

Forward P/E

0.0

P/B

1.68

Book value

$1.73

EPS (TTM)

$-1.00

52-week high

$7.80

52-week low

$1.31

50-day MA

$2.63

200-day MA

$3.56

Beta

1.97

Analyst view

Analysts rate PepGen Ltd a buy (4 buy, 0 hold, 1 sell out of 5) with an average price target of $10.19.

Shareholding

Insiders

0.23%

Institutions

82.85%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	28.97%
COMMODORE CAPITAL LP	6.46%
Viking Global Investors LP	5.03%
LAURION CAPITAL MANAGEMENT LP	3.97%
Vivo Capital, LLC	3.36%
Vanguard Capital Management, LLC	2.80%
Awm Investment Company Inc	2.64%
Millennium Management LLC	2.58%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PepGen Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.